Caris Life Sciences, Inc.
CAI
$31.40
$2.498.61%
NASDAQ
| 03/31/2025 | |||||
|---|---|---|---|---|---|
| Revenue | 49.88% | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | 49.88% | ||||
| Cost of Revenue | 17.02% | ||||
| Gross Profit | 118.51% | ||||
| SG&A Expenses | 9.51% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 3.45% | ||||
| Operating Income | 37.16% | ||||
| Income Before Tax | 7.61% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | 7.61% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | 7.61% | ||||
| EBIT | 37.16% | ||||
| EBITDA | 31.69% | ||||
| EPS Basic | 6.12% | ||||
| Normalized Basic EPS | 8.41% | ||||
| EPS Diluted | 6.12% | ||||
| Normalized Diluted EPS | 8.41% | ||||
| Average Basic Shares Outstanding | 0.88% | ||||
| Average Diluted Shares Outstanding | 0.88% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||